Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › About Us › Our Staff › John Gilmore

John Gilmore

Staff Reporter
Phone Number
212-651-5628
Email
[email protected]

Articles Authored by John Gilmore

Apr 23, 2020

Inivata Expects New Minimal Residual Disease, Recurrence Assay to Support Pharma Trials

Premium

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

Apr 07, 2020

Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction

Premium

The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.   

Aug 15, 2019

GeneCentric Therapeutics to Launch Phase II Validation Study for Head and Neck Cancer Subtyper

Premium

The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.

Jul 10, 2019

Eutropics Drug-Response Platform Being Used by Tolero Pharma in Phase II AML Rx Study

Premium

The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.

May 31, 2019

Single-Cell Sequencing Proves Useful for Tracking Drug-Resistant AML Mutation Progression

Premium

Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.

May 17, 2019

Novigenix Developing NGS Version of Early Colorectal Cancer Detection Test

Premium

The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.

May 16, 2019

Liquid Biopsy Approach Identifies Mutations to Predict Ovarian Cancer Treatment Response

Premium

The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.

May 07, 2019

Kiyatec Targeting Clinical Oncology Space With 3D Cell Culture Technology

Premium

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.

May 03, 2019

Startup My Personal Therapeutics to Apply AI, Fruit Fly Models for Cancer Rx Recommendations

Premium

The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.

Apr 12, 2019

OncoCell Targets Cancer Prognostic Space With Phagocyte-Based Collection Technology

Premium

OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.